Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3U51

Src in complex with DNA-templated macrocyclic inhibitor MC1

Summary for 3U51
Entry DOI10.2210/pdb3u51/pdb
Related3U4W
Related PRD IDPRD_001023
DescriptorProto-oncogene tyrosine-protein kinase Src, macrocyclic inhibitor MC1 (3 entities in total)
Functional Keywordsprotein kinase, src-like inactive conformation, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceGallus gallus (chicken)
Total number of polymer chains4
Total formula weight64636.39
Authors
Seeliger, M.A.,Liu, D.R.,Georghiou, G.,Kleiner, R.E.,Pulkoski-Gross, M. (deposition date: 2011-10-10, release date: 2012-02-22, Last modification date: 2024-10-30)
Primary citationGeorghiou, G.,Kleiner, R.E.,Pulkoski-Gross, M.,Liu, D.R.,Seeliger, M.A.
Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles.
Nat.Chem.Biol., 8:366-374, 2012
Cited by
PubMed Abstract: Protein kinases are attractive therapeutic targets, but their high sequence and structural conservation complicates the development of specific inhibitors. We recently identified, in a DNA-templated macrocycle library, inhibitors with unusually high selectivity among Src-family kinases. Starting from these compounds, we developed and characterized in molecular detail potent macrocyclic inhibitors of Src kinase and its cancer-associated 'gatekeeper' mutant. We solved two cocrystal structures of macrocycles bound to Src kinase. These structures reveal the molecular basis of the combined ATP- and substrate peptide-competitive inhibitory mechanism and the remarkable kinase specificity of the compounds. The most potent compounds inhibit Src activity in cultured mammalian cells. Our work establishes that macrocycles can inhibit protein kinases through a bisubstrate-competitive mechanism with high potency and exceptional specificity, reveals the precise molecular basis for their desirable properties and provides new insights into the development of Src-specific inhibitors with potential therapeutic relevance.
PubMed: 22344177
DOI: 10.1038/nchembio.792
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.241 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon